scholarly article | Q13442814 |
P356 | DOI | 10.1007/S11064-018-2638-0 |
P698 | PubMed publication ID | 30267378 |
P2093 | author name string | Ricardo Titze-de-Almeida | |
Simoneide Souza Titze-de-Almeida | |||
Ana Carolina Martins Domingues | |||
Camila Hillesheim Horst | |||
Cínthia Yara da Silva Ribeiro | |||
Elaine Del Bel Guimarães | |||
Franciele Schlemmer | |||
Gabriel Ginani Ferreira | |||
Natália de Aguiar Montenegro | |||
Rafael Rocha de Andrade | |||
P2860 | cites work | Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153 | Q24633965 |
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method | Q25938999 | ||
The prediagnostic phase of Parkinson's disease | Q26768732 | ||
Involvement of microRNA in microglia-mediated immune response | Q26851399 | ||
Parkinson's disease: animal models and dopaminergic cell vulnerability | Q28080503 | ||
Repression of alpha-synuclein expression and toxicity by microRNA-7. | Q29542272 | ||
Parkinson's disease: mechanisms and models | Q29547424 | ||
Chronic systemic pesticide exposure reproduces features of Parkinson's disease | Q29614763 | ||
A highly reproducible rotenone model of Parkinson's disease | Q30490799 | ||
Toxin-induced models of Parkinson's disease | Q33844749 | ||
Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration | Q33915341 | ||
Development of microRNA therapeutics is coming of age. | Q33991443 | ||
Convergence of miRNA expression profiling, α-synuclein interacton and GWAS in Parkinson's disease | Q34049272 | ||
Brain derived neurotrophic factor (BDNF) expression is regulated by microRNAs miR-26a and miR-26b allele-specific binding. | Q34110230 | ||
The Promise of MicroRNA Replacement Therapy | Q34134295 | ||
MicroRNA-7 protects against 1-methyl-4-phenylpyridinium-induced cell death by targeting RelA. | Q34197681 | ||
MicroRNAs in Parkinson's disease. | Q34247027 | ||
MicroRNA expression profile of the hippocampus in a rat model of temporal lobe epilepsy and miR-34a-targeted neuroprotection against hippocampal neurone cell apoptosis post-status epilepticus. | Q34418730 | ||
Description of Parkinson's disease as a clinical syndrome. | Q35170978 | ||
MicroRNA-7 Promotes Glycolysis to Protect against 1-Methyl-4-phenylpyridinium-induced Cell Death | Q35583229 | ||
Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration | Q35838968 | ||
Pathogenesis of nigral cell death in Parkinson's disease | Q36122869 | ||
Parkinson disease | Q36319286 | ||
Tissue-specific control of brain-enriched miR-7 biogenesis | Q36557067 | ||
MicroRNA-7 Regulates the Function of Mitochondrial Permeability Transition Pore by Targeting VDAC1 Expression. | Q36744745 | ||
MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson's disease | Q36804513 | ||
MicroRNAs in neurodegenerative diseases and their therapeutic potential. | Q37946984 | ||
Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts | Q37955871 | ||
Neuroinflammation in Parkinson's disease. | Q37968058 | ||
miRNA-Based Therapeutic Strategies | Q38092617 | ||
The 200-year journey of Parkinson disease: Reflecting on the past and looking towards the future | Q38557032 | ||
MicroRNA-7: A miRNA with expanding roles in development and disease. | Q38627553 | ||
Therapeutic approaches in Parkinson's disease and related disorders | Q38691406 | ||
The involvement of Eag1 potassium channels and miR-34a in rotenone-induced death of dopaminergic SH-SY5Y cells | Q38713790 | ||
MicroRNA-7 activates Nrf2 pathway by targeting Keap1 expression | Q38829042 | ||
MicroRNA-Let-7a regulates the function of microglia in inflammation | Q38848278 | ||
Advances in markers of prodromal Parkinson disease | Q38992302 | ||
Parkinson's: a syndrome rather than a disease? | Q39060020 | ||
The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market | Q39227810 | ||
Old and new challenges in Parkinson's disease therapeutics. | Q39273471 | ||
Relationship of circulatory BDNF with cognitive deficits in people with Parkinson's disease | Q39947360 | ||
Animal models of α-synucleinopathy for Parkinson disease drug development | Q40106906 | ||
MicroRNA-7 inhibits neuronal apoptosis in a cellular Parkinson's disease model by targeting Bax and Sirt2 | Q40684945 | ||
MicroRNA-34a upregulation during seizure-induced neuronal death | Q42560262 | ||
Characterization of motor, depressive-like and neurochemical alterations induced by a short-term rotenone administration | Q42680857 | ||
The ladder rung walking task: a scoring system and its practical application | Q42949417 | ||
MicroRNA profiling and the role of microRNA-132 in neurodegeneration using a rat model | Q45169578 | ||
Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy | Q46354756 | ||
MicroRNAs and Target Genes As Biomarkers for the Diagnosis of Early Onset of Parkinson Disease. | Q47102033 | ||
Parkinson's disease - 200 years: the outstanding contribution of "Old Hubert". | Q47224543 | ||
microRNAs in Parkinson's Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches. | Q47564833 | ||
Dysregulated microRNAs in neural system: Implication in pathogenesis and biomarker development in Parkinson's disease | Q47721166 | ||
Loss of MicroRNA-7 Regulation Leads to α-Synuclein Accumulation and Dopaminergic Neuronal Loss In Vivo | Q47959536 | ||
Neuroinflammation - A major cause for striatal dopaminergic degeneration in Parkinson's disease. | Q48027557 | ||
Tiny But Mighty: Promising Roles of MicroRNAs in the Diagnosis and Treatment of Parkinson's Disease | Q48171300 | ||
Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson's disease model in rats | Q48490989 | ||
Low BDNF is associated with cognitive impairments in patients with Parkinson's disease | Q48704277 | ||
Differential expression of miR-34a, miR-141, and miR-9 in MPP+-treated differentiated PC12 cells as a model of Parkinson's disease. | Q52598590 | ||
miR-7 Replacement Therapy in Parkinson's Disease | Q64876756 | ||
Delivery of miRNA-Targeted Oligonucleotides in the Rat Striatum by Magnetofection with Neuromag®. | Q64987729 | ||
MicroRNAs in Parkinson's disease | Q88111994 | ||
Let-7a promotes microglia M2 polarization by targeting CKIP-1 following ICH | Q90573454 | ||
P433 | issue | 11 | |
P304 | page(s) | 2132-2140 | |
P577 | publication date | 2018-09-28 | |
P1433 | published in | Neurochemical Research | Q15716728 |
P1476 | title | Signature of Aberrantly Expressed microRNAs in the Striatum of Rotenone-Induced Parkinsonian Rats | |
P478 | volume | 43 |